drugset / Trial / NCT05815485

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485

Phase 2/3 Active not recruiting 144 enrolled The University of Texas Medical Branch, Galveston
RandomizedSequentialQuadruple-blindTreatment

Summary

A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.

Timeline

Start
2023-05-04
Primary completion
2026-04
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azeliragon Small molecule 20 mg

Indications